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 Previous theoretical models of bulimia nervosa (BN) and binge eating disorder (BED) 
have implicated cross-domain risk-taking behaviour as a significant maintenance factor in both 
disorders. The current study sought to test this hypothesis by administering the Balloon 
Analogue Risk Task (BART) to 25 women with BN or BED and 27 healthy comparison women 
without history of an eating disorder. Furthermore, we tested the effect of a divided dose of 
64IU oxytocin on risk-taking behaviour in the BART. Contrary to our hypothesis, women with 
BN or BED did not exhibit baseline differences in performance on the BART in the placebo 
condition (t = 1.42, df = 50, p = .161, d = 0.39). Oxytocin did not have a main effect on 
performance in the BART (F = 0.01, df = 1, p = .907, η2partial < .001); however, there was an 
interaction such that participants in the BN/BED participant group, compared to the healthy 
comparison group, demonstrated safer behaviour on the BART specifically in the oxytocin 
condition, but not in the placebo condition (F = 4.29, df = 1, p = .044, η2partial = .082). These 
findings cast doubt on the common assumption that individuals with BN and BED exhibit 
greater risk-taking behaviour in all domains and add to evidence that oxytocin plays a 
functional role in modulating behaviours which entail trade-offs between reward approach and 
risk in humans. We recommend that future dose-response studies further investigate the effect 
of oxytocin on reward approach behaviour in women with recurrent binge eating behaviour 
and the clinical significance of this effect. 






Recurrent loss-of-control binge eating characterises the DSM-5 eating disorders 
bulimia nervosa (BN) and binge eating disorder (BED) 1. Binge eating behaviour is associated 
with significant distress, guilt, and shame 1-3, and detracts from the overall quality of life of 
affected individuals 4. 
Furthermore, populations with recurrent binge eating behaviour, including those with 
BN and BED, have been found to exhibit heightened levels of risk-taking behaviour, as 
evidenced by the high comorbidity of BN and BED with substance abuse disorders and self-
harm behaviour 5, 6. The role of impulsivity in binge eating behaviour has been well-studied, 
and has been proposed to account for higher levels of risk-taking behaviour in populations with 
recurrent binge eating 7 However, there is evidence to suggest that both generalised reward 
approach processes and impulsivity contribute to trans diagnostic risk-taking behaviour, and 
that each set of processes is both conceptually and functionally distinct. 
In the domain of adolescent risk-taking behaviour, for example, it has been observed 
that adolescents exhibit heightened levels of risk-taking in a virtual driving task when observed 
by peers versus when completing the task alone 8. These increases in risk-taking behaviour 
were found to be associated with heightened BOLD responses in the ventral striatum and 
orbitofrontal cortex, two regions strongly associated with reward processing 9. No difference 
in BOLD response was observed in prefrontal “cognitive control circuits” between conditions 
8. Whilst care must be taken when making inferences from neuroimaging data to the structure 
of cognitive architecture, these data are at least compatible with the hypothesis that risk-taking 
is driven by a dual process incorporating the conflicting tendencies for both reward approach 
and danger avoidance. 
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The separability of reward-seeking and disinhibition in driving risk-taking behaviour is 
also supported by previous literature finding that levels of impulsivity and generalised reward-
seeking follow separate development curves throughout adolescence and early adulthood 10. 
Indeed, it has been proposed that the convergence of high levels of reward-seeking with high 
levels of impulsivity account for the greater vulnerability to risk-taking behaviour observed in 
adolescents 10. 
However, the role of reward-seeking, versus impulsivity, in driving risk-taking 
behaviour has received relatively less attention in empirical literature pertaining to adults with 
recurrent binge eating behaviour. Nonetheless, both conceptual and empirical formulations of 
risk-taking suggest that reduced reward-seeking should have the consequent effect of also 
reducing risk-taking behaviour 11.  
 One laboratory task measuring risk-taking behaviour is the Balloon Analogue Risk 
Task (BART) 14. In the BART, participants aim to maximise a virtual "reward" in a game-like 
task that entails gambling earnings made within each trial as participants continue to seek 
greater overall reward. Therefore, the risk posed by continued responding taps into the ratio of 
participants’ tendency for reward approach versus punishment sensitivity 15, 16. Studies 
recruiting large community samples have found greater risk-taking behaviour on the BART 
among disinhibited, as opposed to restrained, eaters 17, 18, although this effect appears to be 
moderated by prior food consumption 18 and exposure to food images 17.  
Studies administering the BART in clinical eating disorder populations, however, have 
not yielded a clear pattern of results. Manasse, Forman, Ruocco, Butryn, Juarascio and 
Fitzpatrick 19, for example, found no differences on the BART between obese individuals with 
and without BED. Neveu, Fouragnan, Barsumian, Carrier, Lai, Nicolas, Neveu and Coricelli 20 
found that individuals with BN tend to exhibit less risky behaviour in the BART following 
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exposure to food, versus neutral, images, but did not exhibit overall differences in behaviour 
compared to control participants. The study conducted by Neveu, Fouragnan 20, however, was 
limited by low sample size, and the study conducted by Manasse and colleagues 19 administered 
only 10 trials in the BART, while the BART was originally validated across 30 trials of 
balloons with the same probability of explosion. Therefore, limiting the task to 10 trials also 
limited power to detect differences between individuals with and without binge eating 
behaviour.  
On the whole, however, the general pattern of responding on the BART in samples with 
subclinical binge eating behaviour has indicated greater levels of risk-taking behaviour, which 
is in line with studies finding greater risk-taking tendencies on other measures in populations 
with clinical levels of binge eating behaviour 7. In the current study, we therefore sought to 
investigate whether participants with clinical levels of recurrent binge eating behaviour would, 
indeed, be found to exhibit greater risk-taking tendencies on the BART given the greater 
sample size 20 combined with a greater number of BART trials compared to previous 
investigations 19. 
Subsequently, it was of interest to examine whether the hypothesised risk-taking 
tendencies in women with recurrent binge eating could be reduced via modulation of 
underlying reward-seeking. Intranasal oxytocin supplementation has emerged as a new 
investigational approach to manage hedonic and over-eating behaviour in healthy and 
overweight men 21-24 and in BN 25. While oxytocin may partially impact food intake via the 
integration of central and peripheral homeostatic satiety signals 26, an increasing body of 
evidence suggests that the effects of oxytocin on feeding are also mediated by the modulation 
of reward processes 21, 23, 24. For example, the fact that oxytocin has been found to significantly 
curb eating of palatable food in sated healthy normal-weight men, but not homeostatic eating 
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in fasted conditions, suggests that exogenous oxytocin administration has a stronger effect on 
reward-driven, as opposed to homeostatic eating 21, 22, 24. 
With regards to the mechanism of effect of oxytocin on reward processing, it may be 
the case that exogenous oxytocin administration modulates dopaminergic functioning in 
mesolimbic regions. This hypothesis is supported by a range of pre-clinical studies, which have 
indicated that oxytocin directly stimulates dopamine release within the striatum, and reduces 
the likelihood of conditioned place preference to morphine in opioid-tolerant rats after a period 
of withdrawal 27. A recent review of the myriad direct and indirect effects of oxytocin in 
modulating opioid seeking and withdrawal effects has further highlighted the role of oxytocin 
in modulating reward-related central functions of noradrenaline, methamphetamine, serotonin, 
and glutamate 28. 
In humans, 24IU intranasal oxytocin administration has been found to increase blood-
oxygenated-level dependent (BOLD) response to images of high, versus low, calorie foods 
within the ventromedial prefrontal cortex, supplementary motor area, ventrolateral prefrontal 
cortex, and anterior cingulate cortex of healthy men 23. Of functional significance, the oxytocin-
induced enhanced BOLD response in the right ventrolateral prefrontal cortex when viewing 
high- versus low-calorie food images was inversely correlated with the consumption of sweet 
ingredients in a breakfast meal.  While hypotheses stemming from these findings are still 
speculative, it may be the case that oxytocin enhances cognitive control over hedonic eating 
behaviour. In a similar study conducted in healthy adult women, the authors found a trend-
level effect of 24IU oxytocin administration in successfully supporting the intentional 
reduction of food craving in response to food images 29. On the whole, previous preliminary 
evidence has therefore supported a role for oxytocin in modulating reward processing. 
However, it is not yet clear to what extent oxytocin modulates eating behaviour or general 
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reward approach behaviours in the context of risk-taking tendencies in women with recurrent 
loss-of-control binge eating 25, 30.  
In the current study, we sought to compare the performance of women with clinical 
levels of recurrent binge eating on the BART to that of control women without previous history 
of an eating disorder. Furthermore, we also aimed to investigate the differential effect of 
intranasal oxytocin on risk-taking in the BART in women with BN and BED compared to 
healthy controls. Based on theoretical models suggesting the existence of cross-domain risk-
taking 31, we hypothesised that women with BN and BED would demonstrate greater baseline 
risk-taking behaviour on the BART in the placebo condition, relative to women without 
previous history of an eating disorder. Additionally, given previous research indicating that 
oxytocin induces a down-regulation of reward seeking in men, we hypothesised that a divided 
dose of 64IU intranasal oxytocin, versus placebo, would be associated with reduced risk-taking 
behaviour in the BART in women, and that this effect would be stronger in women with BN 
and BED due to higher trait levels of risk-taking behaviour.  
Methods 
Participants 
 Fifty-two women participated in the current study. Given that recurrent binge eating 
behaviour was the primary trait of interest in the current study, and that populations with BN 
and BED are both characterised by recurrent loss-of-control binge eating behaviour, we 
therefore recruited a heterogeneous sample of women who met criteria for either disorder. 
Twenty-five women met DSM-5 criteria for BN or BED at the time of the study and twenty-
seven comparison women had no history of an eating disorder and no current psychiatric 
disorder 1. Participants were recruited via the internal research circular at King’s College 
London, the website for the UK eating disorders charity Beat, and through flyers posted on 
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community bulletin boards. By chance, an unequal number of participants with BN (n = 20) 
versus BED (n = 5) volunteered to take part in the study during the recruitment period. Ethical 
approval for the current study was granted by the London – Camberwell St Giles NHS Research 
Committee (reference: 14/LO/2115). 
 Inclusion criteria for the study were as follows: age between 18 and 40 years 
old, English fluency, and right-handedness (due to an MRI scan which was conducted within 
the battery of tasks). Exclusion criteria included pregnancy, severe psychiatric comorbidity 
(e.g., current or previous history of substance abuse disorder, psychosis), currently smoking > 
5 cigarettes per day (past 6 months), consuming > 21 units of alcohol per week,  uncompensated 
general medical conditions that could alter eating habits (e.g., diabetes, hypothyroidism), 
history of a neurological condition (e.g., epilepsy), a significant visual impairment not 
corrected by eyewear, currently suffering from a cold or flu (as this can affect nasal absorption 
of the oxytocin), contraindication to MRI scans, and current intake of medication that might 
potentially interact with oxytocin (e.g., Prostaglandins). 
 Eligibility for the current study was determined through a phone screening, which 
included an interview using the eating disorders module of the Structured Clinical Interview 
for DSM-5 – Research Version (SCID) 1. Phone screenings were conducted by MSc and PhD 
students who had received training in the correct use of SCID for DSM-5. 
Seven participants in the BN/BED participant group self-reported at least one comorbid 
psychiatric disorder: 5 women had comorbid depression, 4 women had borderline personality 
disorder, 4 women had comorbid generalised anxiety disorder, 1 woman had obsessive-
compulsive disorder, 1 woman had social anxiety, and 1 woman had an autism spectrum 
disorder. At the time of the study, 7 women were taking an antidepressant, 1 woman was taking 
an antipsychotic drug, and 1 woman was taking a mood stabiliser. Participants with BN and 
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BED reported an average binge eating frequency of 14.14 episodes over the past 28 days (SD 
= 9.88).  The women with BN endorsed an average frequency of self-induced vomiting equal 
to 10.40 occasions over the past 28 days (SD = 13.61), an average laxative abuse frequency of 
5.13 occasions over the past 28 days (SD =  8.35), an average frequency of “hard exercise 
intended to control weight or shape” equal to 7.31 occasions over the past 28 days (SD = 8.57), 
and one participant reported using diuretic pills on 4 occasions over the past 28 days.  
Participants self-reported their use of hormonal contraception or the first day of their 
most recent menstrual period and this information was used to determine menstrual phase at 
the time of the study for each participant. Twenty-two participants reported taking hormonal 
contraception at the time of the study. Fifteen women completed the study in the follicular 
phase of the menstrual cycle and thirteen women completed the study in the luteal phase of the 
menstrual cycle. Menstrual phase data were missing for two women. Descriptive statistics 
regarding the age, BMI, and education level of the BN/BED and comparison participant groups 
are presented in Table 1. 
Procedure 
 The current study used a double-blind placebo-controlled crossover design. Each 
participant attended the laboratory for an initial orientation visit and two experimental visits. 
Each participant completed an online battery of psychological tests between the orientation 
visit and the first experimental visit. Two of the tests, the Depression, Anxiety, and Stress 
Scales and the Eating Disorders Examination – Questionnaire version, will be described in 
further detail below. During each experimental visit, participants self-administered a divided 
dose of 64IU intranasal oxytocin or an equal volume of a placebo nasal spray. The order of 
oxytocin versus placebo administration was pseudo-randomised for each participant, such that 
the same number of participants received oxytocin on the first, versus the second, visit. 
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Experimental study visits were held two days apart to ensure that each woman was in the same 
phase of the menstrual cycle during each visit. Perfusion data analysing the central effects of 
oxytocin suggest that carryover effects from oxytocin administration on the first experimental 
visit to the second experimental visit are highly unlikely 32. 
 The first 40IU dose of intranasal oxytocin, or equal volume of placebo, was 
administered at approximately 5.50pm during each experimental visit. Participants 
subsequently underwent an arterial spin labelling (ASL) scan and fMRI scan, in which they 
were presented with images and flavours of water and chocolate milk. These neuroimaging 
results are not reported in the current paper. We chose to administer a 40IU dose of oxytocin 
prior to the fMRI scan in order to replicate the Kim, Eom 25 protocol, which found an effect of 
oxytocin on eating behaviour in women with BN at this dose. We additionally chose this dose 
in order to replicate the protocol of a previous study investigating the effects of intranasal 
oxytocin on cerebral blood perfusion in men 33. A comparison analysis with the previous ASL 
data found in men is currently in preparation for publication. 
However, previous findings in humans have suggested that peak central effects of 40IU 
intranasal oxytocin occur 39-51 minutes following administration 32, thus suggesting the need 
for an additional dose after this time. Therefore, following the conclusion of the fMRI scan, 
each participant self-administered the remaining 24IU of oxytocin or equal volume of placebo 
at approximately 7.10pm. Following this second dose of oxytocin each participant completed 
the Balloon Analogue Risk Task, which is described below. At the conclusion of the study, 
participants were prompted to indicate whether they had received oxytocin or placebo on that 
occasion to test the effectiveness of drug blinding. Drug blinding was found to be effective, as 
participants guessed drug condition correctly on 57 out of the total 104 visits (54.8% of visits), 
which was not significantly different from chance (p = .377). There was not a significant 
difference in the frequency of binge eating episodes in the 24-hr period following oxytocin 
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administration, versus placebo administration, among the participants with BN and BED (see 
Supplementary Material). 
The Balloon Analogue Risk Task 
 The Balloon Analogue Risk Task (BART) is a validated measure of risk taking 
behaviour, which is presented on a computer 14. Each participant is presented with a total of 30 
balloon trials. During each trial, the participant is informed that each additional click of the 
computer mouse will add one pump to the balloon, which is associated with an additional 
virtual £0.05 added to their total task bank. Once the participant believes they have collected 
enough money for that task trial, they press on a button reading “Collect” to collect their total 
earnings for that task trial and proceed to the next trial. However, each balloon is programmed 
to explode after a different random number of pumps. Participants do not collect any money 
on trials where the balloon explodes before the participant chooses to collect their earnings. 
 The BART yields three measures of risk-taking tendency: the adjusted average pump 
count, total pump count, and total explosion count. The adjusted average pump count is 
sensitive to general risk-taking tendency on trials without a balloon explosion, as the pump 
count for trials in which the balloon explodes are excluded from the adjusted average pump 
count measure. A greater adjusted average pump count therefore indicates greater risk-taking 
tendency. The total number of balloon explosions captures continued risk-taking tendency after 
experiencing previous “punishment” for that risk-taking behaviour (in the form of prior balloon 
explosions). The adjusted average pump count is generally considered superior to the total 
pump count, which has an artificial ceiling on pumps imposed on trials in which the balloon 
does explode, thus potentially artificially suppressing variance between individuals’ 
performance 14. In line with standard administration of the BART, the total pump count will 
therefore not be considered in the current paper 14. As both adjusted average pump count and 
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total number of balloon explosions both tap into general risk-taking tendency, these measures 
are positively correlated with each other (r = .91) 14, 34. However, previous work has found 
interpersonal differences in responding to “win” versus “loss” trials, depending on whether the 
balloon exploded in the previous trial. Specifically, compared to adults, adolescents are more 
sensitive to the previous trial’s outcome, responding with more pumps after win trials and fewer 
pumps after loss trials 35. Additionally, men are more likely to continue to respond with a 
greater number of pumps after loss trials 36. Given that the total number of balloon explosions 
taps into continued risk-taking following previous loss trials, there is evidence to suggest that 
total number of balloon explosions additionally captures risk tolerance following previous loss, 
which is not captured by the adjusted average pump count. Accordingly, we have 
operationalised our hypotheses regarding risk-taking tendency in the BART in terms of both 
the adjusted average pump count and total number of balloon explosions. 
Psychometric Tests 
 Depression, Anxiety, and Stress Scales. The Depression, Anxiety, and Stress Scales, 
21-item version (DASS) is a short measure of negative emotions experienced over the course 
of the past week for the individual 37. Each item is presented as a 4-point Likert scale, anchored 
as 0 (“Did not apply to me at all”), 1 (“Applied to me some degree, or some of the time”), 2 
(“Applied to me to a considerable degree or a good part of the time”), and 3 (“Applied to me 
very much or most of the time”). The total score for each subscale of the 21-item DASS is 
calculated by summing participants’ responses to the items for each subscale and multiplying 
this sum by two. Higher scores for each subscale therefore indicate greater levels of depression, 
anxiety, and stress, respectively. Each subscale of the DASS was associated with very good or 
excellent internal consistency reliability in the current study: Depression subscale α = 0.96; 
Anxiety subscale α = 0.88; Stress subscale α = 0.93. The DASS-21 exhibits good discriminant 
and convergent validity, when results are compared against other psychometric measures of 
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depression and anxiety 38. Descriptive statistics associated with the DASS for each participant 
group are presented in Table 2. 
 Eating Disorder Examination – Questionnaire Version. The Eating Disorder 
Examination – Questionnaire Version (EDE-Q) is a self-report questionnaire measuring eating 
disorder psychopathology and the frequency of eating disorder behaviours 39. The 
psychopathology section of the EDE-Q contains four subscales presented in the form of a 7-
point Likert scale: a Restraint subscale, an Eating Concern subscale, a Weight Concern 
subscale, and a Shape Concern subscale. The Likert scale prompts participants to report on 
how many days they exhibited each item of eating disorder psychopathology, in which 
response to each item are anchored from 0 (“No days”) to 6 (“Every day”). Each subscale of 
the EDE-Q was associated with excellent internal consistency reliability in the current sample: 
Restraint subscale α = 0.92; Eating Concern subscale α = 0.93; Shape Concern subscale α = 
0.97; Weight Concern subscale α = 0.94. The EDE-Q is associated with acceptable criterion 
validity, with significantly different mean scores for each subscale among individuals with, 
versus without, a current eating disorder 40. Descriptive statistics associated with the EDE-Q 
subscales for each participant group are reported in Table 3. 
Statistical Analyses 
 All analyses were conducted in IBM SPSS Statistics version 24. Differences in 
performance on the BART in the placebo condition between women in the BN/BED group and 
comparison women were analysed using Student’s t-test. The effects of oxytocin and eating 
disorder status on the adjusted average pump count and total balloon explosions in the BART 
were analysed with 2 x 2 mixed-design ANOVAs. The independent variables for each analysis 
were eating disorder status (healthy control versus BN/BED) and drug condition (placebo 




 The data were first inspected for outliers and assumptions of normality. There were no 
outliers (Z > |3.0|) in the Adjusted Pump Count or Total Explosions variables. Both variables 
were approximately normally distributed (skew < |2.0|, kurtosis < |9.0|) 41. Descriptive statistics 
for the BART data are presented in Table 4. Correlations between the adjusted average pump 
count variable and the total explosion variable within the healthy control group were r = .87 (p 
< .001) and r = .91 (p < .001), for the placebo and oxytocin conditions, respectively. 
Correlations between the adjusted average pump count variable and the total explosion variable 
within the BN/BED group were r = .90 (p < .001) and r = .95 (p < .001), for the placebo and 
oxytocin conditions, respectively. Given the high correlation between the adjusted average 
pump count variable and the total explosion variable and the fact that there were only two main 
analyses, we deemed it excessively conservative to control for multiple comparisons using a 
Bonferroni correction due to the high risk of a Type II error 42. 
Adjusted Average Pump Count 
We tested baseline differences between women with BN/BED and comparison women 
on the adjusted average pump count using Student’s t-test. There was no significant difference 
between the two participant groups on the adjusted average pump count in the placebo 
condition (t = 1.11, df = 50, 95% CI [-2.95, 10.29], p = .270, d = 0.31). We tested the influence 
of oxytocin and eating disorder status on the adjusted average pump count using a 2x2 mixed-
design ANOVA. Participants without history of an eating disorder did not exhibit a significant 
difference on the average adjusted average pump count variable compared to participants in 
the BN/BED group (F = 2.99, df = 1, p = .090, η2partial  = .059). The main effect of drug condition 
on the adjusted average pump count was also non-significant (F = 0.02, df = 1, p = .888, η2partial 
< .001), as was the Drug Condition*Eating Disorder Status interaction (F = 0.90, df = 1, p = 
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.348, η2partial = .018). A line graph depicting the adjusted average pump count for each 
participant group and drug condition is depicted in Supplementary Figure 1. 
Total Explosions 
There was no significant difference in balloon explosions between the healthy 
comparison (HC) and BN/BED participant group in the placebo condition (t = 1.42, df = 50, 
95% CI [-0.58, 3.43], p = .161, d = 0.39). We tested the influence of oxytocin and eating 
disorder status on the total number of balloon explosions using a 2x2 mixed-design ANOVA. 
The main effect of drug condition on total number of explosions was not significant (F = 0.01, 
df = 1, p = .907, η2partial < .001).  Participants in the HC group exhibited a significantly greater 
number of balloon explosions (F = 4.06, df = 1, p = .050, η2partial = .078). There was a significant 
interaction between drug condition and eating disorder status: the HC group exhibited a 
numerically greater number of balloon explosions in the oxytocin condition compared to the 
placebo condition, while participants in the BN/BED group had fewer balloon explosions in 
the oxytocin condition compared to the placebo condition (F = 4.29, df = 1, p = .044, η2partial = 
.082). A line graph depicting the number of total balloon explosions for each participant group 
in each drug condition is presented in Supplementary Figure 2. 
Post hoc t-tests revealed that the difference in total balloon explosions between placebo 
and oxytocin conditions was not statistically significant when the data was isolated among the 
BN/BED participant group (t = 1.20, df = 23, 95% CI [-0.42, 1.59], p = .241, d = 0.30), nor 
among the healthy comparison participant group (t = -1.82, df = 25, 95% CI [-1.39, 0.09], p = 
.081, d = 0.27). However, the difference in balloon explosions between the two groups did 
depend on drug condition. As stated previously, there was no significant difference in balloon 
explosions between the HC and BN/BED participant group in the placebo condition (t = 1.42, 
df = 50, 95% CI [-0.58, 3.43], p = .161, d = 0.39). However, the HC group did have significantly 
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greater balloon explosions than the BN/BED group in the oxytocin condition (t = 2.50, df = 48, 
95% CI [0.51, 4.71], p = .016, d = 0.71). As reported in Table 5, there were no significant 
correlations between depression, anxiety, stress, or eating disorder psychopathology and 
balloon explosions in the oxytocin or placebo condition among the BN/BED participant group. 
We subsequently conducted a sensitivity analysis to investigate the potential 
moderating effect of menstrual phase (follicular phase, luteal phase, or hormonal 
contraception) on the effect of oxytocin on performance in the BART with 3x2 mixed-design 
ANOVAs for the adjusted average pump count and the total number of balloon explosions. 
There was neither a significant main effect nor a significant interaction with oxytocin for either 
dependent variable. The full results of the ANOVA testing the influence of menstrual phase on 
adjusted average pump count are reported in Supplementary Table 1, and the results of the 
ANOVA testing the influence of menstrual phase on the total number of balloon explosions 
are reported in Supplementary Table 2. 
Discussion 
The current study aimed to test differences in risk-taking performance on the BART 
among women with and without clinical levels of recurrent binge eating, which includes 
women with both BN and BED, as compared to healthy comparison women. Additionally, we 
investigated the effect of a divided dose of 64IU intranasal oxytocin on risk-taking behaviours 
in the BART among women with BN and BED, as well as women without prior history of an 
eating disorder. We hypothesised that women with BN and BED would demonstrate greater 
risk-taking behaviour on the BART in the placebo condition. This hypothesis was not 
supported, as there were no significant differences in performance on the BART between the 
BN/BED and HC participant groups in the placebo condition. We also hypothesised that prior 
administration of intranasal oxytocin, versus placebo administration, would be associated with 
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reduced risk-taking behaviour on the BART. Our second hypothesis was also not supported as 
there was no overall effect of oxytocin on the adjusted average pump count or total balloon 
explosion count in the BART. Our final hypothesis was that the effect of oxytocin on reducing 
risk-taking behaviour on the BART would be stronger in women with BN and BED, compared 
to women without history of an eating disorder. Our final hypothesis was partially supported, 
as oxytocin was associated with lower risk-taking tendencies among the BN/BED, versus 
healthy comparison, participant group for the total balloon explosions count. However, there 
was no such significant moderating effect for the adjusted average pump count variable.  
Despite the fact that the moderation effect between participant group and drug condition 
did not reach significance for the adjusted average pump count variable, it is interesting to note 
that the direction of effect was in the same direction as for the balloon count variable. That is, 
participants in the HC group exhibited numerically greater risk-taking tendency compared to 
the BN/BED participant group in the placebo condition, and this difference was enhanced 
further in the oxytocin condition. That is, the healthy control group displayed numerically 
higher risk-taking in the oxytocin versus placebo condition for both variables, and the BN/BED 
participant group displayed numerically lower risk-taking in the oxytocin versus placebo 
condition for both variables. The lack of significant differences observed in the adjusted 
average pump count variable is likely a result of the greater variability in performance on this 
measure. It would therefore be interesting to investigate further in future studies with larger 
sample sizes in order to ensure adequate power. This replication is especially important given 
that we did not statistically control for the two analyses conducted. On the whole, however, 
given that the same pattern of effect was observed for both BART variables, these findings 
therefore suggest that the effect of oxytocin on risk-taking tendencies in the BART is 
moderated by baseline individual differences. 
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The differential effect of oxytocin on risk-taking performance in the BART may relate 
to differences in oxytocin functioning among women with BN compared to healthy comparison 
women. For example, Kim, Kim, Kim, Shin and Treasure 43 have found that the G allele of the 
rs53576 oxytocin receptor gene polymorphism is associated with greater risk for BN. Similarly, 
Micali, Crous-Bou, Treasure and Lawson 44 found that the GG variant of the same gene is 
associated with greater binging and purging behaviour in women. Micali and colleagues 44 also 
found evidence of a gene X environment interaction, such that the AG/GA variant of the 
rs2254298 oxytocin receptor gene polymorphism is associated with greater binging and 
purging behaviour specifically in the context of poor maternal care. This pattern of findings 
suggests that differences in oxytocinergic functioning play a functional role in recurrent binge-
purge behaviour. Additionally, one can speculate that the administration of exogenous oxytocin 
may differentially affect risk-taking tendencies via different patterns of central receptor binding 
in each participant group. It is possible that these differences may be related to neural circuits 
including the nucleus accumbens and ventral tegmental area, both of which contain a high 
density of oxytocin receptors and hold great significance in underpinning appetite behaviour 
and the processing of reward receipt; however, this hypothesis requires further evidence for 
corroboration 45.  
With regards to the lack of statistically significant baseline differences in risk-taking on 
the BART between HC and BN/BED groups, the current results add to a mixed field of findings 
on the BART among participants with disinhibited eating. In non-clinical samples of 
participants with disinhibited eating, defined by higher scores on the Disinhibition scale of the 
Three Factor Eating Questionnaire 46, greater levels of risk-taking behaviour on the BART have 
been observed following prior exposure to food images and food consumption 17, 18. The 
presentation of food stimuli was replicated in the current study given that participants viewed 
images and received small sips of chocolate milk during the course of the fMRI task conducted 
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prior to the BART. However, we failed to observe greater risk-taking behaviour in the BN/BED 
participant group in the placebo condition. 
By contrast to previous research in sub-clinical samples of disinhibited eaters, previous 
studies recruiting clinical samples of participants with BN or BED found similar findings to 
those reported in the current study. That is, there was no difference in responding on the BART 
among obese participants with or without BED 19, nor between participants with BN and 
healthy comparison participants 20. On the whole, these findings demonstrate that individuals 
with BN and BED do not demonstrate greater risk-taking on the BART and, if anything, instead 
exhibit numerically smaller risk-taking tendency. 
With regards to limitations in interpreting the current findings, it should be noted that 
tasks such as the BART have been previously criticised for their limited utility in measuring 
the type of impulsive behaviour generally exhibited by individuals with clinical levels of 
recurrent binge eating. For example, Leitch and colleagues 18 found that women with 
disinhibited eating tended to display higher levels of “Reflective impulsivity”, defined by a 
failure to compile and evaluate relevant information before making a decision, as compared to 
tendencies to perform differently on measures of “Impulsive actions” and “Impulsive choices”. 
Additionally, it is also possible that laboratory tasks involving virtual rewards may lack the 
reward value for participants which would elicit behaviours representative of real-world risk-
taking, and more general reward-approach behaviours. Indeed, a similar measure of risk-taking 
behaviour, the Iowa Gambling Task, has recently been criticised for being poorly correlated 
with self-reported real-life risk-taking behaviour 47, leading to increased interest in the BART 
as an alternative  measure of decision-making in risk-taking scenarios. Future validation studies 
would be useful in more firmly establishing the ecological validity of risk-taking tasks among 
populations with binge eating behaviour. 
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Limitations of the current study also include small sample size, which limited our power 
to detect small effects. Additionally, the neural effects of oxytocin are moderated by dose 48 
time and method of administration 32, so it is possible that a different pattern of effects would 
have been observed using different doses or methods of administration. It would also be 
interesting to further explore differences with and without prior exposure to images of food or 
calorie-dense drinks and without prior administration of the fMRI scan, which may have 
affected responding on the BART by exposing participants to an unfamiliar stressor. Given 
differences in hormonal secretion across the course of circadian cycles 49, which may have 
interacted with the effect of the exogenously-administered oxytocin, it should also be noted 
that the current results may not generalise to different times of day (e.g., in the morning or early 
afternoon). Finally, given the possibility for error inherent in participants self-reporting 
menstrual phase, future studies can improve accuracy in assessing the interaction between 
menstrual phase and exogenous oxytocin by testing blood concentrations of follicle stimulating 
hormone. 
Clinical Implications 
Previous research has described BN as being characterised by elevated levels of both 
reward and punishment sensitivity 50. The fact that BN is commonly comorbid with substance 
use disorders 51 has contributed to the hypothesis that reward approach behaviours tend to “win 
out” over fear of punishment across life domains 52, 53. However, the current findings add to 
previous work using the BART to suggest that elevated risk-taking behaviour is not always 
evident in BN/BED. Previous work has suggested that elevated levels of risk-taking behaviour 
may exist predominantly in subgroup of people with BN comorbid with either  borderline 
personality disorder 51 or attention-deficit/hyperactivity disorder 54. Future research would 
therefore be helpful to determine whether there is differential responsiveness to reward, versus 
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punishment, in women with comorbid BN and borderline personality disorder versus women 
without a comorbid personality disorder. 
Conclusion 
To conclude, the current study aimed to replicate previous studies comparing 
performance on the BART between women with clinical levels of recurrent binge eating to 
comparison women without history of an eating disorder. We further aimed to investigate the 
influence of intranasal oxytocin on risk-taking in the BART among women with BN and BED 
and comparison women without history of an eating disorder. There were no significant 
baseline differences in performance on the BART between women with and without BN or 
BED in the placebo condition. We found evidence of a significant interaction for the balloon 
explosion variable such that a divided dose of 64IU oxytocin enhanced initial numerical 
differences in risk-taking between the participant groups: increasing risk-taking in the healthy 
control group and decreasing risk-taking in the BN/BED participant group. Although not 
reaching significance, the same trend was observed for the adjusted average pump count 
variable. Future studies with greater power would be useful in further clarifying whether cross-
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Descriptive demographic data 
 Healthy Control (n = 27)  BN/BED (n = 25) 
 Mean(SD) Median(IQR) Skew Mean(SD) Median(IQR) Skew 
Age 24.04(3.65) 24.00(6.00) 0.78 25.46(6.39) 23.50(10.00) 0.95 




5.43(1.70) 6(4) -0.70 4.63(1.79) 4.5(3) 0.08 
Note. BN = bulimia nervosa; BED = binge eating disorder; IQR = interquartile range; BMI = 
body mass index; RQF = Regulated Qualifications Framework. 
 
Table 2 
Descriptive statistics for the Depression, Anxiety, and Stress Scales (21-item version) 
Note. BN = bulimia nervosa; BED = binge eating disorder; EDE-Q = Eating Disorder 
Examination – Questionnaire Version. 
 
  
 Healthy Control (n = 25) BN/BED (n = 25)     












10.00(12.00) 1.06 1.69 -5.97 25.35 < .001 




Descriptive statistics for the Subscales of the Eating Disorder Examination – Questionnaire 
Version 
Note. BN = bulimia nervosa; BED = binge eating disorder; EDE-Q = Eating Disorder 
Examination – Questionnaire Version. 
 Healthy Control (n = 26) BN/BED (n = 25)   
 Mean(SD) Median(IQR) Skew Mean(SD) Median(IQR) Skew U p 
EDE-Q 
Restraint 
















Descriptive statistics for performance on the Balloon Analogue Risk Task, separated by eating disorder status 
 Healthy Control (n = 27) BN/BED (n = 25) 
 Placebo Oxytocin Placebo Oxytocin 
 M SD M SD M SD M SD 
Adjusted Average Pump Count 37.62 10.656 38.43 12.033 33.95 13.061 31.95 10.926 
Total Explosions 8.70 3.760 9.19 3.950 7.28 3.422 6.58 3.387 





Pearson correlations between the total balloon explosions among the BN/BED participant group and the DASS and EDE-Q scales 
 1 2 3 4 5 6 7 8 
1. Total Explosions(PL) -        
2. Total Explosions (OT) .76***        
3. DASS Stress Scale -.01 -.06       
4. DASS Depression Scale -.02 -.22 .69***      
5. DASS Anxiety Scale .22 .27 .67*** .35     
6. Restraint .05 .27 .10 -.12 .16    
7. Eating Concern .14 .31 .16 -.18 .27 .48*   
8. Shape Concern -.04 .17 .08 -.03 .17 .51* .71***  
9. Weight Concern .05 .18 .31 -.03 .33 .41* .78*** .81*** 
Note. BN = bulimia nervosa; BED = binge eating disorder; DASS = Depression, Anxiety, and Stress Scales; EDE-Q = Eating Disorder 
Examination – Questionnaire version; OT = oxytocin condition; PL = placebo condition. 
* p < .05. 




Supplementary Figure 1. The influence of oxytocin on the adjusted average pump count 
variable. ED = eating disorder participant group; HC = healthy control participant group. 
Error bars represent confidence intervals. 
Supplementary Figure 2. The influence of oxytocin on total balloon explosions. ED = eating 
disorder participant group; HC = healthy control participant group. Error bars represent 
confidence intervals. 
